Imulan_Slide3
Imulan_Slide1
Imulan_Slide2

Developing a new approach for the treatment of atopic dermatitis in dogs

IMULAN BioTherapeutics, LLC is a privately-owned company developing new immune modulators from our T-Cell Receptor (TCR) peptide platform.  IMULAN is in late stage development of a new canine atopic dermatitis treatment using a new, first-in-class immuno-therapeutic (TCR peptides).  Dog atopy and allergic dermatitis affect millions of dogs in the United States, and our immunological approach for canine atopy targets the immune cells which trigger dog allergies.  We are also designing studies for other diseases including feline stomatitis, FeLV, FIV, and systemic mycosis.

Recent Posts

Pet Owner Info

atopic dermatitis in dogs, dog atopy

IMULAN cannot give advice directly to pet owners concerning our atopic dermatitis treatment program. Please have your veterinarian contact us for updates on our dog atopy clinical trials. You can also visit CanineAtopicDermatitis.com for clinical trial information.

Our TCR Technology

Little Molecule

TCR stand for T-Cell Receptor (TCR), which are the gateway receptors to the immune system. The TCR peptides engage these receptors to modulate T-helper cell activity. T-helper (Th) cells are the central regulators of the allergen response. After evaluating a number of peptides, IMULAN has selected an optimized lead TCR peptide for canine atopic dermatitis. Studies are underway to gain approval for veterinary medicine for the treatment of atopic dermatitis in dogs. T-helper cell 2 (Th2) cells secrete a number of cytokines such as interleukin-31 (IL-31), IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13. These cytokines drive the release of immunoglobulins, like immunoglobulin-E (IgE), and other factors which cause atopy. Thus, the Th2 is the master cell driving allergic skin disease in various animals including dogs.

Since IMULAN's TCR immunotherapeutic targets the cells responsible for atopy, our approach proposes to offer veterinarians a far more comprehensive approach for the treatment of atopic dermatitis compared to blocking single cytokines, cytokine receptors, or anti- mmunoglobulins (like IgE).

The TCR Difference

What's on the horizon? Certain tyrosine kinase inhibitors and / or JAK inhibitors (masitinib, oclacitinib) and anti-IgE and anti-CD20 antibodies are also considerations for canine atopy. However, the TCR technology is very different than drug or antibody approaches, so should NOT be confused with these technologies. Contact IMULAN today to find out why our approach is different!

Other Diseases for TCR

Scientist Microscope

TCR has been studied in a variety of other diseases owing to its upstream mechanism of action. TCR therapeutic peptides have demonstrated significant results in models of retroviral infection, canine cardiomyopathy, canine fungal infections, and feline stomatitis. IMULAN anticipates formal programs for several new diseases in 2013.